NuCana

NCNA · NASDAQ

$0.9853+$0.0253 (+2.64%)TodayMarket closed · Oct 23, 7:30 PM ET

Prev close $0.96

About NCNA

NuCana Plc is a clinical stage biopharmaceutical company. The firm is focused on developing treatment outcomes for patients with cancer by applying its ProTide technology. The firm's pipeline includes NUC-7738 and NUC-3373. NUC-7738 is an anti-cancer agent that disrupts Ribonucleic acid (RNA) polyadenylation, profoundly impacts gene expression in cancer cells and targets multiple aspects of the tumor microenvironment. NUC-7738 is in the Phase II part of a Phase I/II study which is evaluating NUC-7738 as a monotherapy in patients with advanced solid tumors and in combination with pembrolizumab in patients with melanoma. NUC-3373 is a chemical entity derived from the nucleoside analog 5-fluorouracil, a chemotherapy agent. NUC-3373 is being evaluated in a Phase Ib/II modular study (NuTide:303) of NUC-3373 in combination with the PD-1 inhibitor pembrolizumab for patients with advanced solid tumors and in combination with docetaxel for patients with lung cancer.

Employees: 11
Headquarters: Edinburgh
Listed: Sep 28, 2017
Sector: Health Care
Industry: Biotechnology
Website: nucana.com

Leadership

NuCana executives
Name	Title	Since	Age
Andrew Kay	—	—	69
Hugh Griffith	—	2008	57
Ian Webster	—	—	—
Theresa Bruce	—	—	—
Jeffrey Bloss	—	—	68
David Harrison	—	—	65
Cyrille Leperlier	—	—	71
Elliott Levy	—	—	66
Martin Mellish	—	—	67
Bali Muralidhar	—	—	45
Christopher Brinzey	—	2021	—

Suppliers and customers

Price correlation is over one year: 1 means the stocks move together, -1 opposite

NuCana suppliers and customers
Company	Relationship	Country	Correlation
Morvus Technology Ltd.	Supplier and customer	GB	—
University of Cardiff	Supplier and customer	GB	—
Abingworth Management Ltd.	Supplier and customer	GB	—
Baillie Gifford & Co.	Supplier and customer	GB	—
Drum income Plus REIT	Supplier	GB	—
Sofinnova Partners Societe par Actions Simplifiee	Supplier and customer	FR	—

Similar companies

Companies in the same industry as NuCana

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.